Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled RETRO- Study
Achieving remission is the most important treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying anti-rheumatic drugs (DMARD) about half of RA patients reach a state of disease remission, raising the question about tapering or stopping anti-rheumatic treatment. The aim of this study was to assess the effect of a controlled DMARD tapering regimen on treatment costs and work productivity in RA patients in remission.
101 RA patients in sustained remission (DAS28 <2.6 for more than 6 months), enrolled in the multicenter randomized controlled RETRO Study, were analyzed (1). Patients either continued DMARDs (arm1), tapered dose by 50% (arm 2) or entire stopped DMARDs after tapering (arm 3) for one year. Assessment of DMARD costs and work productivity was done every three months in all 101 patients including those remaining in remission and those relapsing a re-starting their original DMARD regimen.
RA patients treated with conventional DMARDs, baseline quarterly treatment costs of 154€ remained stable in arm 1 (156€), while decreasing to 81€ in arm 2 and 75€ in arm 3. In patients treated with biologic DMARDs quarterly treatment costs were 5,708€ at baseline. They remained stable in arm1 (5,533€) and decreased to 3,036€ in arm 2 and 2,668€ in arm 3. Overall DMARD costs were reduced by 327,292€ within one year, while outcome was very good with patients either remaining in remission or immediately regaining remission when exposed to original DMARD regimen after relapse.
Controlled tapering of DMARD treatment leads to effective reduction of treatment costs in RA patients in sustained remission.
To cite this abstract in AMA style:Hagen M, Figueiredo CP, Cobra JF, Haschka J, Reiser M, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Finzel S, Tony HP, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nüßlein H, Alten R, Henes JC, Krüger K, Schett G, Rech J. Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/effects-of-dmard-tapering-on-treatment-costs-and-work-productivity-in-rheumatoid-arthritis-patients-an-analysis-from-the-prospective-randomized-controlled-retro-study/. Accessed December 2, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-dmard-tapering-on-treatment-costs-and-work-productivity-in-rheumatoid-arthritis-patients-an-analysis-from-the-prospective-randomized-controlled-retro-study/